Literature DB >> 11302414

Mood disorders associated with interferon treatment: theoretical and practical considerations.

P Malek-Ahmadi1.   

Abstract

OBJECTIVE: To review the theoretical and clinical aspects of mood disorders associated with interferon treatment and discuss their management. DATA SOURCES: Pertinent and selected laboratory/clinical studies, review articles, letters, abstracts, and book chapters on behavioral and mood-related adverse effects of interferons published in English-language journals in the past two decades were identified by MEDLINE (June 1980-June 2000) and manual searches. DATA SELECTION AND DATA EXTRACTION: All of the publications identified were reviewed, and the relevant data were included. Studies not using criteria for psychiatric diagnosis or instruments for psychiatnc monitoring were excluded. DATA SYNTHESIS: Clinical observations and limited research data suggest that interferon treatment may be associated with mood disorders. Mood-related symptoms induced by interferons emerge in a few days or weeks and tend to be dose dependent. Their severity may necessitate discontinuation of interferon therapy and/or the use of antidepressant or antimanic agents. The mechanisms responsible for inducing or exacerbating mood disorders in interferon-treated patients have not been elucidated. There is limited evidence implicating alterations in the serotonin system.
CONCLUSIONS: While interferon therapy may trigger or induce mood-related symptoms, preexisting or stable concurrent mood disorders in remission do not necessarily constitute a contraindication to treatment with interferons. Mood disorders associated with interferon treatment can present clinical challenges. However, they may promote our understanding of mood disorders in the context of the current biologic theories of depression and mania.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302414     DOI: 10.1345/aph.10172

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

Review 1.  Neuroimmune pharmacology of neurodegenerative and mental diseases.

Authors:  Feng-Shiun Shie; Yun-Hsiang Chen; Chia-Hsiang Chen; Ing-Kang Ho
Journal:  J Neuroimmune Pharmacol       Date:  2010-09-07       Impact factor: 4.147

Review 2.  Hepatitis C: Treatment of difficult to treat patients.

Authors:  Eric G Hilgenfeldt; Alex Schlachterman; Roberto J Firpi
Journal:  World J Hepatol       Date:  2015-07-28

3.  Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.

Authors:  Karen F Murray; James R Rodrigue; Regino P González-Peralta; John Shepherd; Bruce A Barton; Patricia R Robuck; Kathleen B Schwarz
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

Review 4.  Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review.

Authors:  Arne Schäfer; Hans-Ulrich Wittchen; Jochen Seufert; Michael R Kraus
Journal:  Int J Methods Psychiatr Res       Date:  2007       Impact factor: 4.035

5.  Minocycline treatment ameliorates interferon-alpha- induced neurogenic defects and depression-like behaviors in mice.

Authors:  Lian-Shun Zheng; Naoko Kaneko; Kazunobu Sawamoto
Journal:  Front Cell Neurosci       Date:  2015-01-28       Impact factor: 5.505

6.  Back to the Future: The Role of Infections in Psychopathology. Focus on OCD.

Authors:  Alessandra Della Vecchia; Donatella Marazziti
Journal:  Clin Neuropsychiatry       Date:  2022-08

7.  Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment.

Authors:  S H Mellon; O M Wolkowitz; M D Schonemann; E S Epel; R Rosser; H B Burke; L Mahan; V I Reus; D Stamatiou; C-C Liew; S W Cole
Journal:  Transl Psychiatry       Date:  2016-05-24       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.